Evidence
J Addict Med. 2023 Oct 20. doi: 10.1097/ADM.0000000000001233. Online ahead of print.
ABSTRACT
BACKGROUND: Because of a risk of precipitated withdrawal occurring from buprenorphine induction in people who use fentanyl, low-dose inductions are becoming increasingly common. However, little evidence exists on the use of this method in pregnant people.
METHODS: We conducted a case series of all pregnant people treated for opioid use disorder with low-dose buprenorphine induction at the University of Maryland Medical Center between January 1, 2021, and August 22, 2022. Primary outcome was completion of induction regimen. Secondary outcomes were self-report of withdrawal, continuation of buprenorphine until delivery, and return to or continuation of illicit opioid use.
RESULTS: Six pregnant people were prescribed a total of 10 buprenorphine inductions. Five of the 6 pregnant people (83.3%) completed at least 1 induction, none of whom experienced precipitated withdrawal. Two of 6 (33.3%) continued buprenorphine until the time of delivery, and 1 of 6 (16.7%) abstained from illicit opioid use.
CONCLUSIONS: The low-dose buprenorphine induction regimen described was successful in 5 of 6 pregnant individuals. Further research, particularly regarding continuation rates, is needed.
PMID:37862120 | DOI:10.1097/ADM.0000000000001233
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Low-dose Induction of Buprenorphine in Pregnancy: A Case Series
🌐 90 Days
VR Related Evidence Matrix
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Case Series of Individuals Treated with Naltrexone during Pregnancy for Opioid and/or Alcohol Use Disorder
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022
- Efficacy and safety of low-dose esketamine for painless gastrointestinal endoscopy in adults: a systematic evaluation and meta-analysis
- Ethical challenges in the treatment of psychotic pregnancy denial
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
- Augmented Reality Improves Pediatric Mask Induction: A Prospective, Matched Case-Control Study
- Establishing a research agenda for the study and assessment of opioid withdrawal
- Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Integrated care van delivery of evidence-based services for people who inject drugs: A cluster-randomized trial
- Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings
- Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids
- Current concepts in ketamine therapy in the emergency department
- Real-World Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients With Opioid Use Disorder During the COVID-19 Pandemic: Erratum
- Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults
- Positive mood induction does not reduce return of fear: A virtual reality exposure study for public speaking anxiety
- Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo
- Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo
- Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- Sleep Quality in High-Risk Pregnancies: Mixed Methods Results from a Randomized Controlled Trial of a Mindfulness Training Intervention
- Vortioxetine Exposure During Pregnancy and Lactation: A Japanese Case Study of Neonatal Implications and Quantitative Milk and Plasma Analyses
- Overdose from Unintentional Fentanyl Use when Intending to Use a Non-opioid Substance: An Analysis of Medically Attended Opioid Overdose Events
- Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems
- A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
- A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
- Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
- Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth
- Alcohol Withdrawal Severity Measures for Identifying Patients Requiring High-Intensity Care
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Dose-dependent increase in risk of bleeding and bleeding complications in relation to SSRI use at delivery
- Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment
- Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
- Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model
- Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use
- Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use
- Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use
- 10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder
- The effect on perioperative anxiety and emergence delirium of the child or parent's preference for parental accompaniment during anesthesia induction in children undergoing adenotonsillectomy surgery
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Cigarette and E-Cigarette Perceptions About Harm During Pregnancy
- Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus
- Efficacy and safety of perioperative melatonin for postoperative delirium in patients undergoing surgery: a systematic review and meta-analysis
- Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives
- Effect of docosahexaenoic acid and olive oil supplementation on pup weight in alcohol-exposed pregnant rats
Evidence Blueprint
Low-dose Induction of Buprenorphine in Pregnancy: A Case Series
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Low-dose Induction of Buprenorphine in Pregnancy: A Case Series
🌐 365 Days
VR Related Evidence Matrix
- Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
- Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone
- Evidence on Buprenorphine Dose Limits: A Review
- Low Dose Buprenorphine Initiation: A Guide for the Inpatient Clinician
- A Response to the Feasibility of the IPPAS Protocol for Low-dose Buprenorphine Induction
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series
- Case Series of Individuals Treated with Naltrexone during Pregnancy for Opioid and/or Alcohol Use Disorder
- Doing Our Best in a Broken System: The Urgent Need for Expansion of Medication for Opioid Use Disorder Treatments in the United States
- Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report
- Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder
- ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
- Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices
- Buprenorphine Induction: Just a Piece of the Puzzle
- Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen
- Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series
- The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine
- Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
- Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs
- Association between Individual versus Community-level Social Vulnerability and Neonatal Opioid Withdrawal Syndrome among Pregnant Individuals receiving Buprenorphine for Opioid Use Disorder
- Buprenorphine Monoproduct for Buprenorphine/Naloxone Tolerability Problems: Navigating Stigma for Patient-centered Addiction Care without Guideline Support
- Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review
- Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review
- Reliability of urine drug testing among patients on buprenorphine transdermal patch
- Adrenal Crisis Masked as Septic Shock in a Patient With Opioid Use Disorder on Buprenorphine
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Emergency Department Access to Buprenorphine for Opioid Use Disorder
- Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
- Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report
- The End of the X-waiver: Excitement, Apprehension, and Opportunity
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids
- Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care
- Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
- Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Opioids in geriatric units in 14 Belgian hospitals: prevalence, dosage and associated factors
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
- First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations
- Extended-release buprenorphine in pregnancy
- Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021
- Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada
- Validation of a pharmacological imaging challenge using 11C-buprenorphine and 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to study the effects of buprenorphine to the rat brain
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
- Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations
- Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
- Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use
- Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail
- Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products
- Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine
- Reply to: "Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine"
- Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment